undefined undefined
NaN.000
NaN.00%
JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 to $200.
05-03 00:45
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-03 00:44
Repligen Reaffirms 2024 Sales Guidance Of $620M-$650M Versus Consensus Of $637....
05-01 19:34
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.30 by 6.67 percent. This is a 56.25 percent decrease over earnings of $0.64 per share from the same
05-01 19:32
RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – ...
05-01 09:49
It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent perf...
05-01 01:38
Repligen shares are trading higher as life sciences stocks gain following stron...
04-23 20:54
Danaher (NYSE:DHR) shares added ~9% premarket Tuesday after the company topped Street forecasts with its Q1 2024 financials despite ongoing contraction at its biotech business. The U.S.-based life sci...
04-23 18:58
Repligen (RGEN – Research Report) received a Buy rating and price target from C...
04-19 21:15
Some say volatility, rather than debt, is the best way to think about risk as a...
04-16 01:36